Unfavorable outcomes were fewer and safety was similar among participants with diabetes receiving rifapentine/moxifloxacin compared with controls.
Categorised in: EID (Emerging Infectious Disease)
This post was written by senioradmin
Unfavorable outcomes were fewer and safety was similar among participants with diabetes receiving rifapentine/moxifloxacin compared with controls.
Categorised in: EID (Emerging Infectious Disease)
This post was written by senioradmin
Comments are closed here.